'COVID-19 rapid diagnostic test could contain transmission in low- and middle-income countries'

Simple item page
dc.contributor.authorOlalekan, A
dc.contributor.authorIwalokun, B
dc.contributor.authorAkinloye, O.M
dc.contributor.authorPoopola, O
dc.contributor.authorSamuel, T.A
dc.contributor.authorAkinloye, O
dc.date.accessioned2021-07-03T02:40:58Z
dc.date.available2021-07-03T02:40:58Z
dc.date.issued2020-04-01
dc.description.abstractBackground: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has impacted heavily on global health. Although real-time polymerase chain reaction (RT-PCR) is the current diagnostic method, challenges for low- and middle-income countries (LMICs) necessitate cheaper, higher-throughput, reliable rapid diagnostic tests (RDTs). Objective: We reviewed the documented performance characteristics of available COVID-19 RDTs to understand their public health utility in the ongoing pandemic, especially in resourcescarce LMIC settings. Methods: Using a scoping review methodology framework, common literature databases and documentary reports were searched up to 22 April 2020, irrespective of geographical location. The search terms included ‘SARS-CoV-2 AND serological testing’ and ‘COVID-19 AND serological testing’. Results: A total of 18 RDTs produced in eight countries, namely China (6; 33.33%), the United States (4; 22.22%), Germany (2; 11.11%), Singapore (2; 11.11%), Canada, Kenya, Korea and Belgium (1 each; 5.56%), were evaluated. Reported sensitivity ranged from 18.4% to 100% (average = 84.7%), whereas specificity ranged from 90.6% to 100% (average = 95.6%). The testing time ranged from 2 min to 30 min. Of the 12 validated RDTs, the IgM/IgG duo kit with non-colloidal gold labelling system was reported to elicit the highest sensitivity (98% – 100%) and specificity (98% – 99% for IgG and 96% – 99% for IgM). Conclusion: We found reports of high sensitivity and specificity among the developed RDTs that could complement RT-PCR for the detection of SARS-CoV-2 antibodies, especially for screening in LMICs. However, it is necessary to validate these kits locally.en_US
dc.identifier.otherDO - 10.4102/ajlm.v9i1.1255.
dc.identifier.urihttps://ir.unilag.edu.ng/handle/123456789/9464
dc.language.isoenen_US
dc.publisherAfrican Journal of Laboratory Medicine; Vol 9, No 1 (2020)en_US
dc.subjectCoronavirus disease; COVID-19; SARS-CoV-2; rapid diagnostic test; low- and middle-income countries.en_US
dc.title'COVID-19 rapid diagnostic test could contain transmission in low- and middle-income countries'en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
RDT Adesola Olalekan.pdf
Size:
870.22 KB
Format:
Adobe Portable Document Format
Description:
AJLM RDT COVID -19 PUBLICATION
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical Laboratory Science- Scholarly Publications